United Therapeutics Corp.

United Therapeutics is a biotechnology company. The company markets and sells four commercial therapies to treat pulmonary arterial hypertension (PAH): Remodulin? (treprostinil) Injection; Tyvaso? (treprostinil) Inhalation Solution; Orenitram? (treprostinil) Extended-Release Tablets; and Adcirca? (tadalafil) Tablets. The company also markets and sells an oncology product, Unituxin? (dinutuximab) Injection for treatment of high-risk neuroblastoma. The company also engages in research and development of new indications and formulations and delivery devices for its existing products, as well as new products to treat PAH and other conditions. The company also engages in organ transplantation-related technologies.
  • TickerUTHR
  • ISINUS91307C1027
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
Andreas Argyrides ...
  • Liana Moussatos
  • Shveta Dighe

Tyvaso/PH-ILD Setting Positive Tone in 2021 Ahead of Value-Driving Catalysts

Wedbush Research

Wedbush Morning Call - Jan 11 2021 6:56AM

Andreas Argyrides ...
  • Ashiq Mubarack
  • David Nierengarten
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Andreas Argyrides ...
  • Liana Moussatos
  • Shveta Dighe

PRV Bought for $105M Creates Expedited Regulatory Review for Tyvaso DPI™

Wedbush Research

Wedbush Morning Call - Dec 21 2020 6:42AM

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

Andreas Argyrides ...
  • Liana Moussatos
  • Shveta Dighe

Tyvaso/PH-ILD Setting Positive Tone in 2021 Ahead of Value-Driving Catalysts

Wedbush Research

Wedbush Morning Call - Jan 11 2021 6:56AM

Andreas Argyrides ...
  • Ashiq Mubarack
  • David Nierengarten
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Andreas Argyrides ...
  • Liana Moussatos
  • Shveta Dighe

PRV Bought for $105M Creates Expedited Regulatory Review for Tyvaso DPI™

Wedbush Research

Wedbush Morning Call - Dec 21 2020 6:42AM

UNITED THERAPEUTICS is slightly downgraded to Slightly Positive due to an increasingly adverse environment

The independent financial analyst theScreener just slightly lowered the general evaluation of UNITED THERAPEUTICS (US), active in the Biotechnology industry. As regards its fundamental valuation, the title confirms its rating of 4 out of 4 stars while its market behaviour remains unchanged and can be qualified as defensive. However, a marginally less favourable environment forces theScreener to downgrade slightly the title, which now shows an overall rating of Slightly Positive. As of the analysis date October 20, 2020, the closing price was USD 119.17 and its potential was estimated at USD 12...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch